Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|24 CitationsLongevity & CellularFemale-friendly

SS-31 Dosing Protocol: Elamipretide Mitochondrial Guide

Also known as: Elamipretide, Bendavia, MTP-131, Cardiolipin Peptide

Dose Range
0.05 mgResearch range
0Typical research window: 0.05 mg0.5 mg

Studied in published research — not a medical recommendation. Primary protocol (Mitochondrial Support Protocol): 0.05 mg/kg/hr, 1-hour infusion.

Protocol at a Glance
How Often
1-hour infusion

1-hour infusion

A Typical Run
48 weeks in clinical trials

Research-reported range; verify dose against the linked paper. Used in Phase 2 trials for primary mitochondrial myopathy

How It's Taken
Vial

Intravenous infusion

Evidence
Established

Human clinical trials or FDA-approved formulation exists

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 0.05 mg2 units

All U-100: 100 units = 1 mL. 100 doses in the vial at the low end.

Track the doses you run

Save SS-31 (Elamipretide) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

SS-31 (Elamipretide) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$175.99
50mg vial
$3.52/mg
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$39.99 net$79.99
10mg Lyophilized Vial
$4.00/mg$8.00/mg retail
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$250.00
50mg vial
$5.00/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$55.00
10mg vial, sold as “ER-S3”
$5.50/mg
Bulletproof BioLabs
ILS Laboratories HPLC COA COA-2026-7UOKEL, lot BPB-2610-001
US Domestic Vial
Vendor-supplied list price (Nov 7, 2026; store requires login)
$55.00
10mg vial
$5.50/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$58.00
10mg vial
$5.80/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$69.00
10mg vial
$6.90/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-5133749 (99.48%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$84.00
10mg vial
$8.40/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Phase 2/3 Clinical TrialsTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Mitochondrial-Derived Cytoprotective & Bioenergetic Peptide (MDP)
Administration Route
Under-the-skin injection (Intravenous infusion)
2026 FDA & 503A Status
Active Phase 2/3 human clinical trials in 2026; not yet FDA-approved for commercial prescription or 503A bulk pharmacy compounding. Sold strictly as an analytical laboratory reference standard.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval

SS-31 (Elamipretide) is the same active compound as (investigational) (Stealth BioTherapeutics). Not FDA approved in the US.

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. SS-31 (Elamipretide) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

SS-31 is a mitochondria-targeted tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane. It improves mitochondrial function and reduces oxidative stress.

Mechanisms of Action

  • Binds to cardiolipin in inner mitochondrial membrane
  • Improves electron transport chain efficiency
  • Reduces mitochondrial ROS production
  • Preserves mitochondrial cristae structure

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Mitochondrial Support Protocol
reported protocol
0.05 mg/kg/hr1-hour infusion48 weeks in clinical trialsIntravenous infusionclinical trial
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (SS-31 (Elamipretide))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

15 Human9 Animal

Elamipretide is also under phase&#xa0;III clinical development for use in the treatment of dry age-related macular degeneration and mitochondrial myopathies. This article summarizes the milestones in the development of elamipretide leading to this first approval for Barth syndrome.

Limitations: No placebo control reported. Review article — no new primary data.

2026|Drugs
PubMed

Elamipretide Hydrochloride. (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026)

Limitations: Animal study only — human translation uncertain.

2026|American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
PubMed

Further research may expand its application to other diseases involving mitochondrial dysfunction as well as investigate long-term efficacy and safety of the drug. The following review synthesizes current knowledge of the structure, mechanisms of action, and the promising therapeutic role of Elamipretide in stabilizing mitochondrial fitness, improving mitochondrial bioenergetics, and minimizing oxidative stress.

Limitations: No placebo control reported. Review article — no new primary data.

2025|International journal of molecular sciences
PubMed

SS-31@Fer-1 significantly improved H/R-induced cardiomyocyte viability and reduced LDH and CK-MB levels. Compared to the Fer-1 group, SS-31@Fer-1 reduced GSH and increased MDA levels, enhancing mitochondrial integrity and function.

Limitations: Animal study only — human translation uncertain.

2025|Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
PubMed

Additionally, dietary interventions and novel regulators such as adenogens are emerging as promising strategies to modulate mitochondrial function and attenuate kidney disease progression. Future research should address the gaps in understanding the role of mitophagy in CAKUT and optimize targeted delivery systems for precision therapies.

Limitations: No placebo control reported. Review article — no new primary data.

2025|Cells
PubMed

Elamipretide continues to show promise as a potential therapy for mitochondrial disorders. New basic science advances have improved understanding of elamipretide's MOA, enabling a better understanding of the molecular consequences of elamipretide-cardiolipin interactions.

Limitations: No placebo control reported. Review article — no new primary data.

2025|Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
PubMed

Challenges include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence. Advances in smart delivery systems, drug formulations, and predictive models, alongside interdisciplinary collaboration, will be crucial in achieving personalized, effective, and sustainable retinal therapies.

Limitations: No placebo control reported. Review article — no new primary data.

2025|Expert opinion on pharmacotherapy
PubMed

We further demonstrate that telomere elongation during ICM formation is controlled by mitochondrial-nuclear communication at fertilization. Using mitochondrially-targeted therapeutics (BGP-15, MitoQ, SS-31, metformin) we demonstrate that it is possible to modulate the preimplantation telomere resetting process and restore deficiencies in neonatal telomere length.

Limitations: Animal study only — human translation uncertain.

2025|Nature communications
PubMed

Affected males transmit the TAFAZZIN pathogenic variant to all of their daughters and none of their sons. If the TAFAZZIN pathogenic variant has been identified in an affected family member, identification of female heterozygotes and prenatal/preimplantation genetic testing for Barth syndrome are possible.

Limitations: No placebo control reported. Review article — no new primary data.

2025|Trends in biotechnology
PubMed

Here, we showed that increased oxidized cardiolipin (ox-CL) and significant mitochondrial damage were accompanied by increased ALCAT1 expression in the glomeruli of patients with DKD. Similar results were found in db/db mouse kidneys and in cultured podocytes stimulated with high glucose (HG).

Limitations: No placebo control reported.

2024|Cell communication and signaling : CCS
PubMed

Ten patients entered the OLE; 8 reached the week 168 visit. Elamipretide was well tolerated, with injection-site reactions being the most common adverse events.

Limitations: Standard limitations apply. Check original paper for full discussion.

2024|Genetics in medicine : official journal of the American College of Medical Genetics
PubMed

Subjects with mtDNA pathogenic variants or single large-scale mtDNA deletions represented 74% of the MMPOWER-3 population, with 70% in the mtDNA cohort having either single large-scale mtDNA deletions or MT-TL1 pathogenic variants. Most subjects in the nDNA cohort had pathogenic variants in genes required for mtDNA maintenance (mtDNA replisome), the majority of which were in POLG and TWNK.

Limitations: Standard limitations apply. Check original paper for full discussion.

2024|Orphanet journal of rare diseases
PubMed

A novel hierarchical action liposome nanosystem (PHP-DPS@INS) was developed in this study. In terms of delivery, PHP-DPS@INS nanoparticles (NPs) overcame the ocular surface transport barrier by adopting the strategy of "ocular surface electrostatic adhesion-lysosomal site-directed escape".

Limitations: No placebo control reported.

2024|Journal of nanobiotechnology
PubMed

These findings suggest that elamipretide may prevent the progressive development of neurodegenerative diseases via enhancing mitochondrial respiration, mitochondrial biogenesis, mitochondrial fusion, and neural pro-survival pathway, as well as inhibiting mitochondrial fission, oxidative stress, neuroinflammation, toxic protein accumulation, and neural apoptosis. Elamipretide or mitochondrially-targeted peptide might be a targeted agent to attenuate neurodegenerative progression.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2024|Frontiers in integrative neuroscience
PubMed

Participants (N = 218) were randomized (n = 109 elamipretide; n = 109 placebo). The m0ean age was 45.6 years (64% women; 94% White).

Limitations: Standard limitations apply. Check original paper for full discussion.

2023|Neurology
PubMed

Ultimately, we applied asiatic acid (a p38-MAPK agonist) to test whether SS-31 regulated cPLA2 partially through the MAPK-P38 signalling pathway. Our group is the first to suggest that SS-31 promotes functional recovery partially by inhibiting cPLA2-mediated autophagy impairment and preventing LMP and pyroptosis after SCI, which may have potential clinical application value.

Limitations: Animal study only — human translation uncertain.

2023|Journal of neuroinflammation
PubMed

These findings indicated that SS-31 protected against pulmonary fibrosis and inflammation by inhibiting the Nrf2-mediated NLRP3 inflammasome in macrophages. Our data provide initial evidence for the therapeutic efficacy of SS-31 in IPF.

Limitations: Animal study only — human translation uncertain.

2023|Antioxidants (Basel, Switzerland)
PubMed

In a rat MI model, the resulting liposomal composite hydrogel improves cardiac function by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis. This study reports for the first time a liposomal composite hydrogel that can directly target mitochondria of damaged CMs for a feedback-regulated release of encapsulated liposomes to consume the overproduced pathological ROS for improved CM activity and enhanced MI treatment.

Limitations: Animal study only — human translation uncertain.

2022|Advanced healthcare materials
PubMed

In early-phase clinical trials, elamipretide administration has not resulted in any severe adverse events, and it has shown promising improvements in cardiac hemodynamics at highest doses. Nonetheless, additional studies are necessary to describe the long-term safety and efficacy of elamipretide.

Limitations: No placebo control reported. Review article — no new primary data.

2022|Heart failure reviews
PubMed

Parallel reaction monitoring of a subset of phosphorylation sites revealed that the unmodified peptide reporting for Myot S231 increased with age, but not its phosphorylated form and that both phosphorylated and unphosphorylated forms of the peptide covering cMyBP-C S307 increased, but that elamipretide treatment did not affect these changes. These results suggest that changes to thiol redox state and phosphorylation status are two ways in which age may affect mouse heart function, which can be restored by treatment with elamipretide.

Limitations: Animal study only — human translation uncertain.

2022|GeroScience
PubMed

Data with elamipretide across multiple models of disease are especially promising, with results from several studies supporting the use of elamipretide as potential therapy for patients with Barth syndrome, particularly where there is a confirmed diagnosis of cardiomyopathy. This review highlights the challenges and opportunities presented in treating Barth syndrome cardiomyopathy patients with elamipretide and addresses evidence supporting the durability of effect of elamipretide as a therapeutic agent for Barth syndrome, especially its likely durable effects on progression of cardiomyopathy following the cessation of drug treatment and the capability of elamipretide to structurally reverse remodel the failing left ventricle at the global, cellular, and molecular level in a gradual manner through specific targeting of the mitochondrial inner membrane.

Limitations: No placebo control reported. Review article — no new primary data.

2022|Heart failure reviews
PubMed

This review article discusses the potential candidates for AMD therapy and their known mechanisms of cytoprotection in AMD. These target therapeutic candidates include APE/REF-1, MRZ-99030, Ciliary NeuroTrophic Factor (CNTF), RAP1 GTPase, Celecoxib, and SS-31/Elamipretide.

Limitations: No placebo control reported. Review article — no new primary data.

2021|Cells
PubMed

Surprisingly, we did not observe a synergistic effect between the two drugs in the group receiving both etanercept and MTP-131. One possible explanation for the absence of a synergistic effect is that MTP-131 and etanercept may be acting on different portions of the same pathway.

Limitations: No placebo control reported. Review article — no new primary data.

2021|Experimental eye research
PubMed

Mice treated with LPS exhibited mitochondrial dysfunction, oxidative stress, an inflammatory response, neural cell apoptosis, and loss of dendritic spines in the hippocampus, leading to impaired hippocampus-related learning and memory performance in the MWM and contextual fear conditioning test. Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment during behavioral tests.

Limitations: Animal study only — human translation uncertain.

2020|Journal of neuroinflammation
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Not FDA approved
  • •IV administration requires medical setting
  • •Long-term safety data limited
  • •Very expensive
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get SS-31 (Elamipretide), baseline labs & clinician oversight.

Full SS-31 (Elamipretide) $/mg comparison →
50% OFF AUTO-APPLIED$4.00/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy SS-31 (Elamipretide): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Swift Peptides — $3.52/mg (50mg vial, $175.99)
  2. 2. Ascension Peptides — $4.00/mg (10mg Lyophilized Vial, $39.99)
  3. 3. Limitless Peptides — $5.00/mg (50mg vial, $250.00)

Where is the cheapest place to buy SS-31 (Elamipretide)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Swift Peptides at $3.52/mg (50mg vial, $175.99). We compared 8 US suppliers with live, checked prices.

How much does SS-31 (Elamipretide) cost per mg?

Verified US domestic prices currently range from $3.52/mg to $8.40/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is SS-31 (Elamipretide) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.